Cardiology Letters 2022, 31(1):35-47

Proteomic markers associated with the progression of atherosclerosis in type 2 diabetes

Demková K, Yaluri A, Tkáč I

klinika UPJŠ LF a UNLP, Rastislavova 43, 041 90 Košice, Slovenská republika

Atherosclerosis and its complications are the main causes of morbidity and mortality in Western countries. Early detection and treatment of atherosclerosis is thus imperative to improve global health. Identification of subjects at increased risk for atherosclerosis and its complications plays a central role in the worldwide efforts to improve prevention, prediction, diagnosis, and prognosis of atherosclerosis and to decrease the related costs. Despite their high predictive value on population level, traditional risk factors fail to fully predict individual risk. With the recent advances in proteomics, many new risk factors with smallto-moderate effects are likely to be identified. Additionally, individualized risk stratification and targeted therapy may become feasible, each individual could potentially be assessed with a panel of tests for proteomic markers, and on the basis of the individual's composite risk profile, preventive and therapeutic steps could then be undertaken. With a multimarker approach, it may also be possible to identify alterations in pathways involved in atherogenesis, rather than focus on individual risk factors. This review article provides a summary of current vascular biomarkers other than the traditional risk factors, with a special focus on the proteomic markers.

Keywords: biomarkers; proteomic markers; atherosclerosis; type 2 diabetes mellitus

Published: January 1, 2022  Show citation